Biontech Se
- All
- News
- Videos
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
On Omicron vs Vaccines, New Grounds For Cautious Optimism
The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Shots Should Protect From Worst Of Omicron, Says Big Vaccine-Maker
The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.
-
BioNTech Is Working On An 'Omicron' Version Of Its Covid Shot
BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
Moderna's Shot Creates Twice As Many Antibodies As Pfizer, Study Shows
Moderna Inc.'s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
-
Longer 8-Week Gap Between Pfizer Doses Boosts Antibodies, Study Finds
An interval of eight to 10 weeks between doses of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE boosts the effectiveness of the two-shot regimen compared with a shorter interval, a U.K. study found.
-
Israel Finds Probable Link Between Pfizer Covid Shot, Myocarditis
Israel health officials have found a probable link between Pfizer Inc. and BioNTech SE's coronavirus vaccine and dozens of cases of heart inflammation in young men following the second dose of the vaccine, the Health Ministry said late Tuesday.
-
Israel Examines Heart Inflammation Cases After Pfizer Covid Shot
Israel is examining dozens of cases where people experienced heart inflammation after receiving Pfizer Inc. and BioNTech SE's coronavirus vaccine.
-
Pfizer, Moderna Vaccines Highly Effective Even After 1st Shot: US Study
COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced the risk of infection by 80 per cent two weeks or more after the first of two shots, according to data from a real-world study of vaccinated US healthcare personnel and first responders released on Monday.
-
Pfizer, BioNTech Launch COVID-19 Vaccine Trial In Children Under 12
Pfizer Inc and German partner BioNTech SE began testing their COVID-19 vaccine in children under 12, with hopes of expanding vaccination to that age range by early 2022, the U.S. drugmaker said on Thursday.
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
On Omicron vs Vaccines, New Grounds For Cautious Optimism
The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Shots Should Protect From Worst Of Omicron, Says Big Vaccine-Maker
The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.
-
BioNTech Is Working On An 'Omicron' Version Of Its Covid Shot
BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
Moderna's Shot Creates Twice As Many Antibodies As Pfizer, Study Shows
Moderna Inc.'s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
-
Longer 8-Week Gap Between Pfizer Doses Boosts Antibodies, Study Finds
An interval of eight to 10 weeks between doses of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE boosts the effectiveness of the two-shot regimen compared with a shorter interval, a U.K. study found.
-
Israel Finds Probable Link Between Pfizer Covid Shot, Myocarditis
Israel health officials have found a probable link between Pfizer Inc. and BioNTech SE's coronavirus vaccine and dozens of cases of heart inflammation in young men following the second dose of the vaccine, the Health Ministry said late Tuesday.
-
Israel Examines Heart Inflammation Cases After Pfizer Covid Shot
Israel is examining dozens of cases where people experienced heart inflammation after receiving Pfizer Inc. and BioNTech SE's coronavirus vaccine.
-
Pfizer, Moderna Vaccines Highly Effective Even After 1st Shot: US Study
COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced the risk of infection by 80 per cent two weeks or more after the first of two shots, according to data from a real-world study of vaccinated US healthcare personnel and first responders released on Monday.
-
Pfizer, BioNTech Launch COVID-19 Vaccine Trial In Children Under 12
Pfizer Inc and German partner BioNTech SE began testing their COVID-19 vaccine in children under 12, with hopes of expanding vaccination to that age range by early 2022, the U.S. drugmaker said on Thursday.
